PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Smoking Reduction”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed2003

Smoking cessation, smoking reduction, and delayed quitting among smokers given nicotine patches and a self-help pamphlet.

Over-the-counter nicotine replacement raises questions regarding its "real world" efficacy. This was an open-label, prospective study of 223 smokers who received 42 free nicotine patches and a self-help booklet via shopping mall distribution. The overall quit rate 6 months following distribution of the nicotine patches was 22% (50/223), almost the same quit rate found 6 weeks following patch distribution (21%, 47/223). Twelve percent (27/223) were abstinent at both 6 weeks and 6 months. Among the 83 participants who did not quit, cigarettes smoked per day dropped from 28 to 18. A substantial subgroup of quitters (14%) who, although still smoking at 6 weeks, were smoke free at 6 months, and it appears they had purposefully delayed a serious quit attempt. These results support the usefulness of nicotine patches in helping smokers quit, even with only minimal intervention such as a self-help manual.

Female↗
PubMed2001

Effects of smoking reduction during pregnancy on the birth weight of term infants.

This study was undertaken to determine 1) whether reducing tobacco exposure during pregnancy increases the birth weight of term infants and 2) the relative effects of early- and late-pregnancy exposure to tobacco on infant birth weight. Data were obtained from the Smoking Cessation in Pregnancy project, conducted in public clinics in three states (Colorado, Maryland, and Missouri) between 1987 and 1991. Self-reported cigarette use and urine cotinine concentration were collected from 1,583 pregnant smokers at study enrollment and in the third trimester. General linear models were used to generate mean adjusted birth weights for women who reduced their tobacco exposure by 50 percent or more and for those who did not change their exposure. Regression smoothing techniques were used to characterize the relation between birth weight and early exposure and birth weight and third-trimester exposure. Reducing cigarette use was associated with an increase in mean adjusted birth weight of only 32 g, which was not significant (p = 0.33). As third-trimester cigarette use increased, birth weight declined sharply but leveled off at more than eight cigarettes per day. Findings were similar when urine cotinine concentration was used. Women who smoke during pregnancy may need to reduce to low levels of exposure (less than eight cigarettes per day) to improve infant birth weight.

Adult↗
PubMed2006

Population impact--definition, calculation and its use in prevention science in the example of tobacco smoking reduction.

INTRODUCTION: Population Impact is a criterion that can enhance prevention practices and provide a solid foundation for integrating policies and programs for prevention. However, to quantify the population impact of programs a statistical measure is needed. The objective of this article is to (a) deduct a formula to quantify population impact (PI), (b) define the formula for population impact of smoking prevention measures and (c) apply this formula on smoking prevention programs. METHODS: Decision analytical approach. RESULTS: The measurement of PI is defined with four parameters: recruitment, retention, efficacy and prevalence. A formula is mathematically deducted and the PI for different smoking prevention programs is calculated. DISCUSSION: The formula supports decision makers in deciding what prevention measure shows a higher impact on the population, gives hints where to improve the measure to increase the impact, whether recruitment, retention or efficacy needs to be improved and makes it easy to do analyses of costs on the population level. CONCLUSIONS: To enhance prevention practice prevention measures need to provide all parameters to calculate the PI, research needs to focus on all parameters influencing the PI and costs of prevention measures need to be provided.

Algorithms↗
PubMed1995

The relationship of gender, diet patterns, and body type to weight change following smoking reduction: a multivariate approach.

We compared two regression models of posttobacco-reduction weight gain using nutrient intake and other variables as predictors. The first model involved the regression of weight gain, in pounds, against absolute change in the nutrient predictor variables. The second model utilized a data transformation, regressing percent change from initial body weight against change in nutrient:weight ratios. Both models included age, initial body-mass index (BMI), and change in nicotine exposure as additional predictors. Separate analyses were conducted for each gender and for obese and normal-weight participants. The results indicated that adjusting changes in nutrient intake for weight predicted posttreatment weight gain better than absolute changes in nutrient intake. The most accurate prediction was observed for normal-weight individuals, with both genders simultaneously in the model. Increase in weight was predicted by a decrease in nicotine exposure, a decrease in calories per pound, decrease in carbohydrates per pound, and an increase in a carbohydrate:protein ratio. Neither model predicted weight change for obese participants. These findings suggest that adjusting nutrient intake for body weight obviates the need for separate examination of each gender, and that a reduction in nicotine exposure is associated with weight gain. The results are consistent with those studies that attribute postcessation weight gain to decreased metabolic activity and reduction in nicotine intake.

Adult↗
PubMed1995

Emotional self-regulation therapy for smoking reduction: description and initial empirical data.

Self-regulation therapy (Amigó, 1992) is a set of procedures derived from cognitive skill training programs for increasing hypnotizability. First, experiences are generated by actual stimuli. Clients are then asked to associate those experiences with various cues. They are then requested to generate the experiences in response to the cues, but without the actual stimuli. When they are able to do so quickly and easily, therapeutic suggestions are given. Studies of self-regulation therapy indicate that it can be used successfully to treat smoking.

Arousal↗
PubMedDate not supplied

Comprehensive evaluation of a community coalition: a case study of environmental tobacco smoke reduction.

Community coalitions have become an increasingly popular means for addressing community health issues, yet evaluating their effectiveness and performance has presented formidable challenges. To meet the community's need for health program evaluation, public health nurses will need to become better prepared to deal with the complexities of evaluating coalitions and their multifaceted organizational structures. This article presents the methodology and conceptual framework, Targeting Outcomes of Programs (TOP), used to evaluate the performance and impact of a local community coalition. The case study offered here focuses on a tobacco-prevention coalition composed of 15 public and private agencies and their 121 activities. The TOP evaluation model provided the coalition with formative evaluation, needed to improve the coalition's on-going program delivery, and summative evaluation, needed for annual reviews of the coalition's effectiveness and impact in the community. The methodological approach and instrument presented here provide the public health nurse with a solid conceptual framework for approaching such a task.

Community Health Planning↗
PubMed2006

Adolescent smoking continuation: reduction and progression in smoking after experimentation and recent onset.

In the present study, the role of cognitive concepts derived from the Theory of Planned Behavior in adolescent smoking reduction, continuation, and progression was investigated. These concepts include pro-smoking attitudes, perceived social norms regarding smoking, and self-efficacy to resist smoking. Logistic regression analyses were performed on data from 397 Dutch adolescents aged 11-15 years, who had at least once tried smoking. Attitudes, perceived social norms, and self-efficacy, including significant interactions between these three concepts, explained up to 41% of variance in smoking behavior cross-sectionally. Longitudinally, an interaction between pro-smoking attitudes and low self-efficacy increased the chance of reduction in smoking, and all three cognitions inclusive of two interactions between pro-smoking perceived social norms and low self-efficacy or positive attitudes towards smoking predicted progression of smoking. Cognitions may play relatively small roles in adolescent smoking reduction, but do seem to be relevant in progression in smoking after experimentation or recent onset. Interactions between positive attitudes towards smoking and prosmoking perceived social norms provide cumulative risks for adolescents to increase their levels of smoking, whereas interactions between less favorable attitudes and high self-efficacy to resist smoking may provide a protective effect for adolescents to reduce or to quit their smoking.

Adolescent↗
PubMed2004

Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.

PURPOSE: To determine whether sustained-release bupropion promotes smoking reduction leading to smoking cessation among persons who wish to reduce their amount of smoking, but who are unwilling to quit or who perceive themselves as being unable to quit. METHODS: Current smokers were assigned randomly to receive either sustained-release bupropion (150 mg twice daily) or matching placebo. During an initial 6-month smoking reduction phase, those who were willing to quit entered a 7-week cessation phase, during which study medication was continued. RESULTS: Four-week continuous abstinence rates were 14% (41/295) in the bupropion group and 8% (25/299) in the placebo group (P = 0.02) during treatment. However, this benefit did not continue after treatment was stopped; subsequent continuous abstinence rates were 7% (20/295) in the bupropion group and 5% (16/299) in the placebo group (P = 0.50). Similar proportions of subjects entered the cessation phase in both treatment groups (38% [n = 113] of those in the bupropion group and 34% [n = 101] of those in the placebo group), although the time until a cessation attempt was shorter for those taking bupropion (median, 64 days vs. 118 days, P = 0.008). The extent of smoking reduction (measured by urinary cotinine concentrations) among the 327 subjects who did not enter the cessation phase was significantly greater (P <0.05) in those treated with bupropion during the reduction treatment phase, but not during the month 12 follow-up visit (P = 0.25). CONCLUSION: Sustained-release bupropion, when used in smokers initially not willing to make a cessation attempt, can help sustain smoking reduction while subjects are on active medication, reduce the time until the next cessation attempt, and increase short-term abstinence rates. However, these benefits were modest and not sustained after bupropion was discontinued.

Adult↗
PubMed2006

Smoking, smoking cessation, and risk of cardiovascular disease.

Cigarette smoking increases the risk of atherothrombotic clinical events such as myocardial infarction and the effect is dose dependent for persons who continue to smoke. Reductions in smoking habit and smoking cessation are important ways to improve cardiovascular risk and favorably affect primary and secondary prevention of clinical disease. Therapeutic methods to improve smoking reduction and cessation include nicotine replacement, behavioral interventions, and medications (bupropion, clonidine). Improved cessation rates are under active study and include behavioral methods, targeting smokers immediately after myocardial infarction, consideration of depression in smokers, pharmacogenomics to identify persons who may respond more favorably to specific interventions, and newer medications that affect endocannabinoid receptors.

Journal Article↗
PubMed1999

Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands.

The aim of this study was to estimate the healthcare costs of asthma and chronic obstructive pulmonary disease (COPD), in the Netherlands, in 1993. Also studied was the future development of these costs, as a result of ageing and possible changes in smoking behavior. A prevalence-based cost-of-illness approach was used to estimate direct medical costs. Age- and gender-specific data were obtained from representative national registries and large, representative surveys. To model future costs, cost estimates were linked to an epidemiological model based on a dynamic multi-state lifetable. It describes 1 yr changes, from one state to another, that result from ageing, birth, migration, incidence, recovery from asthma and death due to asthma, COPD or other causes, and starting or quitting smoking. Three different scenarios were modelled: 1) a reference scenario which primarily predicts the impact of ageing. 2) an 'attainable' smoking reduction scenario and 3) an 'extreme' smoking reduction scenario. Direct medical costs were estimated to be $US 346 million in 1993. With increasing age, the relative importance of asthma in total asthma and COPD costs decreased from 91% to less than 4%. Annual costs per patient were estimated to be $US 499 for asthma and $US 876 for COPD. The breakdown of costs differed considerably between asthma and COPD. The reference scenario predicted the costs to increase by 60% to reach $US 555 million by 2010, COPD prevention as modelled in the second and the third scenario reduced the projected cost increase from 60%, to 57% and 48%, respectively. Together, the direct costs of asthma and COPD represent 1.3% of the Dutch health care budget. The breakdown of the costs shows different patterns for asthma and COPD. The costs of these diseases are expected to increase by 60% in the near future. In the short run the impact of smoking reduction on reducing this increase is relatively small, but it will be greater in the long run.

Adolescent↗
PubMed2005

Effects of cigarette reduction on cardiovascular risk factors and subjective measures.

STUDY OBJECTIVES: To assess the effect of continued smoking and smoking reduction on cardiovascular biomarkers (eg, WBC count, cholesterol concentrations, BP, heart rate). DESIGN, SETTING, AND PARTICIPANTS: This study, conducted at the University of Minnesota, randomized smokers interested in significantly reducing cigarette use but not quitting to either start 12 weeks of smoking reduction immediately (n = 102), assisted by nicotine replacement therapy, or to a 6-week wait list (n = 49). Those starting smoking reduction were required to reduce smoking by 25% for 2 weeks, 50% for 2 weeks, and 75% during the final 2 weeks. After 6 weeks, the subjects were asked to maintain a 50% reduction or quit. Nicotine gum and, if necessary, nicotine patch were used to achieve reduction goals. The wait list group (n = 49) smoked ad libitum for 6 weeks and then reduced smoking as previously described. MEASUREMENTS AND RESULTS: Cardiovascular biomarkers (eg, WBC count, cholesterol concentrations, BP, heart rate) were assessed at several time points after enrollment. During ad libitum smoking, cardiovascular biomarkers remained relatively stable with correlation coefficients across the various time measurements, ranging from 0.44 to 1.00 (p < 0.01 for all measures). Among successful nonabstinent reducers (64 of 151 subjects), significant improvements were found in many biomarkers (eg, hemoglobin, hematocrit, RBC and WBC counts, lipids, BP, heart rate, respiratory symptoms, all p < 0.0167). CONCLUSIONS: These results show the availability of reliable and dose-sensitive biomarkers and that reduction in smoking can lead to significant but only modest changes in cardiovascular risk factors in healthy smokers. It is not known whether the reductions in cardiovascular risk factors observed after smoking reduction are also associated with reduced disease risk. Additional research is necessary to address this issue.

Adolescent↗
PubMed2003

Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women.

PURPOSE: We conducted this study because the duration of excess lung cancer risk among former smokers has been inconsistently reported, doubt has been raised regarding the population impact of smoking cessation, and differential risk reduction by histologic cell type after smoking cessation needs to be confirmed. METHODS: The Iowa Women's Health Study is a prospective cohort study of 41,836 Iowa women aged 55 to 69 years. In 1986, mailed questionnaires were used to collect detailed smoking history. Age-adjusted lung cancer incidence through 1999 was analyzed according to years of smoking abstinence. Relative risks were estimated using Cox regression analysis. RESULTS: There were 37,078 women in the analytic cohort. Compared with the never smokers, former smokers had an elevated lung cancer risk (relative risk, 6.6; 95% confidence interval, 5.0 to 8.7) up to 30 years after smoking cessation for all former smokers. However, a beneficial effect of smoking cessation was observed among recent and distant former smokers. The risk of adenocarcinoma remained elevated up to 30 years for both former heavier and former lighter smokers. CONCLUSION: The risk for lung cancer is increased for both current and former smokers compared with never smokers and declines for former smokers with increasing duration of abstinence. The decline in excess lung cancer risk among former smokers is prolonged compared with other studies, especially for adenocarcinoma and for heavy smokers, suggesting that more emphasis should be placed on smoking prevention and lung cancer chemoprevention.

Adenocarcinoma↗